What long-term damage can Cosentyx (secukinumab) cause?
Cosentyx is used for inflammatory conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The main long-term risks clinicians watch for are not usually “organ damage” in the way people might mean it (like permanent liver failure), but rather ongoing side effects and infection-related complications over time.
From available publicly reported safety information, the most important long-term concern categories are:
- Infection risk (because it suppresses parts of the immune system), including serious infections. [1]
- Ongoing or new safety signals that may emerge with longer exposure in broader patient use. [1]
What happens if you stay on Cosentyx for years?
Many patients take biologics for years. The key long-term safety questions tend to be:
- Whether infections become more frequent the longer you take it.
- Whether any lab abnormalities develop over time.
- Whether the medication stops working (loss of response) and then changes are needed.
For a patient, the practical “long-term damage” concern is usually management of infections and monitoring rather than a specific, predictable organ-damage pattern. Product safety information emphasizes infection risk and serious infections as the major concern to address over ongoing treatment. [1]
Does Cosentyx cause permanent organ damage (liver, kidneys, lungs)?
Cosentyx’s known safety focus in long-term use is less about a specific, classic pattern of permanent organ toxicity and more about immune suppression-related risks (notably serious infections). [1]
If someone is worried about a particular organ (for example, liver symptoms, breathing problems, or recurrent infections), the right approach is to contact their clinician promptly. Those scenarios aren’t something to “wait out” while continuing a biologic.
Can Cosentyx increase cancer risk or cause long-term malignancy?
Because Cosentyx affects the immune system, many patients ask about cancer risk. The safety profile is monitored continuously, and the drug’s ongoing risk assessment is part of post-marketing surveillance. The key point for patients is that malignancy risk is something regulators track over time, but any definitive long-term conclusions come from accumulated safety monitoring rather than from short trials. [1]
What long-term side effects are patients most concerned about?
Common concerns that matter over longer timelines include:
- Recurrent or serious infections.
- Symptoms that could signal an infection early (fever, worsening cough, painful urination, skin infections).
- Ongoing treatment tolerability and whether side effects persist.
The prescribing/safety information highlights infections, including serious infections, as the primary long-term safety category to watch. [1]
Who should not take Cosentyx (or who needs extra caution long term)?
Extra caution is typically needed for people with:
- Active infections.
- A history of recurrent serious infections.
- Situations where immune suppression could be higher risk.
If you have a history of frequent infections or have had serious infections while on biologics before, that is important to discuss with the prescriber before continuing long-term. [1]
What should you monitor during long-term Cosentyx treatment?
Patients generally need ongoing clinical monitoring for infections and symptom changes. Your prescriber may also use lab monitoring depending on your comorbidities and other medications. The prescribing information emphasizes infection vigilance as a major safety action. [1]
Is there a difference between long-term risk for psoriasis vs psoriatic arthritis vs ankylosing spondylitis?
The drug is the same, but the underlying disease and other medications can change overall risk. Long-term “damage” questions often depend on:
- How active the inflammatory disease is without treatment.
- Whether you take other immunosuppressants (for example, corticosteroids or methotrexate).
- Your infection history and comorbidities.
So the long-term risk picture is partly about your total treatment plan, not only Cosentyx.
Sources
[1] Drug information and safety monitoring, Cosentyx (secukinumab) — DrugPatentWatch.com: https://www.drugpatentwatch.com/